Updates in the management of pediatric dyslipidemia.
Child
Humans
Proprotein Convertase 9
/ metabolism
Dyslipidemias
/ metabolism
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Hyperlipidemias
Cardiovascular Diseases
/ drug therapy
Hyperlipoproteinemia Type II
/ drug therapy
Atherosclerosis
/ drug therapy
Anticholesteremic Agents
/ therapeutic use
Angiopoietin-Like Protein 3
Journal
Current opinion in lipidology
ISSN: 1473-6535
Titre abrégé: Curr Opin Lipidol
Pays: England
ID NLM: 9010000
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
12
7
2023
pubmed:
22
3
2023
entrez:
21
3
2023
Statut:
ppublish
Résumé
Pediatric dyslipidemias increase the risk of atherosclerosis and clinical cardiovascular disease and are the leading cause of morbidity and mortality. Lifestyle modifications and pharmacotherapies have measurably improved abnormal lipids and reduced cardiovascular events. The review will focus on current standards of care and investigative medications with the potential to improve cardiovascular health in children and adults. Lifestyle interventions and statins remain cornerstones in the treatment of pediatric hyperlipidemias. Bile acid sequestrants and ezetimibe continue to be used in the pediatric population as well. In recent years, successful clinical trials have approved use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in children with familial hypercholesterolemia. Use of angiopoietin-like protein 3 (ANGPTL3) inhibitors is also promising as it causes marked improvement in low-density lipoprotein cholesterol with safe side effect profiles. Additional medications undergoing pediatric clinical trials include inclisiran, bempedoic acid, and lomitapide. Recent advances in pharmacotherapy, especially for treatment of familial hypercholesterolemia, greatly impact treatment of dyslipidemias in children. Despite the overall progress in the development of these medications, therapies targeted towards treating hypertriglyceridemia have lagged behind. Continuing research for the treatment of pediatric dyslipidemias remains an important endeavor to reduce the risk of atherosclerosis and future cardiovascular events in children.
Identifiants
pubmed: 36942877
doi: 10.1097/MOL.0000000000000879
pii: 00041433-990000000-00035
doi:
Substances chimiques
PCSK9 protein, human
EC 3.4.21.-
Proprotein Convertase 9
EC 3.4.21.-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Anticholesteremic Agents
0
ANGPTL3 protein, human
0
Angiopoietin-Like Protein 3
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
156-161Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Murphy SL, Kochanek KD, Xu J, Arias E. Mortality in the United States, 2020 [Internet]. In: NCHS Data Brief. Hyattsville, MD: National Center for Health Statistics; 2021 [Accessed 3 March 2023]. pp. 1-8. Report no.: 427. Available from: https://www.cdc.gov/nchs/products/databriefs/db427.htm .
Luirink IK, Wiegman A, Kusters DM, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med 2019; 381:1547–1556.
Ferrari F, Martins VM, Rocha VZ, Santos RD. Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia. Expert Opin Pharmacother 2021; 22:483–495.
Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004; 160:407–420.
Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35:2146–2157.
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart L, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128:S213–S256.
Patel A, Patni N. Evaluation and management of lipids and lipoproteins in children and adolescents. Endocrinol Metab Clin North Am 2022; 51:573–588.
Yu-Poth S, Zhao G, Etherton T, et al. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr 1999; 69:632–646.
Schefelker JM, Peterson AL. Screening and management of dyslipidemia in children and adolescents. J Clin Med 2022; 11:6479.
Elsevier, Inc., Daniels SR, Couch SC. Lipid disorders in children and adolescents. In: Sperling MA, Majzoub JA, Menon RK, Stratakis C, editors. Sperling pediatric endocrinology. 5 ed.2021; 1004–1021.
Anagnostis P, Vaitsi K, Kleitsioti P, et al. Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. Endocrine 2020; 69:249–261.
Kusters DM, Caceres M, Coll M, et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr 2015; 166:1377–1384.
van der Graaf A, Cuffie-Jackson C, Vissers MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008; 52:1421–1429.
Stein EA, Marais D, Szamosi T, et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr 2010; 156:231–236.
Tonstad S, Knudtzon J, Sivertsen M, et al. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 1996; 129:42–49.
Colletti RB, Neufield EJ, Roff NK, et al. Niacin treatment of hypercholesterolemia in children. Pediatrics 1993; 92:78–82.
Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385:341–350.
Santos RD, Stein EA, Hovingh GK, et al. Long-term evolocumab in patients with familial hypercholesterolemia. J Am Coll Cardiol 2020; 75:565–574.
Santos RD, Ruzza A, Hovingh GK, et al. Evolocumab in pediatric heterozygous familial hypercholesterolemia. N Engl J Med 2020; 383:1317–1327.
Santos RD, Ruzza A, Hovingh GK, et al. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. Lancet Diabetes Endocrinol 2022; 10:732–740.
Gaudet D, Ruzza A, Bridges I, et al. Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia. J Clin Lipidol 2022; 16:676–684.
U.S. Food & Drug Administration. FDA approves add-on drug for ages 10 & up with rare forms of high cholesterol [Internet]. U.S. Food & Drug Administration; 2021 [Accessed 21 January 2023]. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-drug-ages-10-rare-forms-high-cholesterol .
Bruckert E, Caprio S, Wiegman A, et al. Efficacy and safety of alirocumab in children and adolescents with homozygous familial hypercholesterolemia: phase 3, multinational open-label study. Arterioscler Thromb Vasc Biol 2022; 42:1447–1457.
ClinicalTrials.gov. An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia [Internet]. U.S National Library of Medicine; 27 April 2018 [updated 19 August 2022; accessed 16 February 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT03510884 .
Reijman MD, Schweizer A, Peterson ALH, et al. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. Eur J Prev Cardiol 2022; 29:1361–1368.
Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020; 382:1507–1519.
ClinicalTrials.gov. Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia (ORION-16) [Internet]. U.S National Library of Medicine; 3 December 2020 [updated 8 February 2023; accessed 16 February 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT04652726 .
ClinicalTrials.gov. Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia (ORION-13) [Internet]. U.S National Library of Medicine; 9 December 2020 [updated 18 January 2023; accessed 16 February 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT04659863 .
Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA 2019; 322:1780–1788.
ClinicalTrials.gov. A Phase 2 Clinical Study in Children With HeFH Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1) [Internet]. U.S. National Library of Medicine; 23 January 2023 [Accessed 16 February 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT05694260 .
Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med 2020; 383:711–720.
ClinicalTrials.gov. Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia [Internet]. U.S. National Library of Medicine; 24 January 2018 [updated 10 November 2022; accessed 16 February 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT03409744 .
ClinicalTrials.gov. Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia [Internet]. U.S National Library of Medicine; 18 January 2020 [updated 1 February 2023; accessed 16 February 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT04233918 .
U.S. Food & Drug Administration. FDA approves add-on therapy for patients with genetic form of severely high cholesterol [Internet]. U.S. Food & Drug Administration; 2021 [Accessed 21 January 2023]. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-therapy-patients-genetic-form-severely-high-cholesterol-0 .
Ben-Omran T, Masana L, Kolovou G, et al. Real-world outcomes with lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia. Adv Ther 2019; 36:1786–1811.
ClinicalTrials.gov. Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH) [Internet]. U.S National Library of Medicine; 23 December 2020 [updated 5 April 2022; accessed 16 February 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT04681170 .
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290:140–205.
Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019; 380:11–22.
Stackpole KMW, Ollberding NJ, Smith LA, et al. Omega-3 use for the treatment of hypertriglyceridemia, low high-density lipoprotein cholesterol levels, and nonalcoholic fatty liver disease in children with obesity. Child Obes 2021; 17:357–364.
Del-Rio-Navarro BE, Miranda-Lora AL, Huang F, et al. Effect of supplementation with omega-3 fatty acids on hypertriglyceridemia in pediatric patients with obesity. J Pediatr Endocrinol Metab 2019; 32:811–819.
Wang D, Liu B, Tao W, et al. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev 2015; 2015:CD009580.
FDALabel [Internet]. U.S Food & Drug Administration; 2009. Tricor (fenofibrate) tablet; [updated 6 February 2023; accessed 3 March 2023]; [19 pages]. Available from: https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/84b2af1b-365e-4723-ac5f-bc826ec47772/spl-doc .
FDALabel [Internet]. U.S Food & Drug Administration; 2007. Gemfibrozil tablet; [updated 19 January 2023; accessed 3 March 2023]; [13 pages]. Available from: https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/8a32a8a7-3a9a-cb02-e053-2a95a90a8aa5/spl-doc .
Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. The Lancet 2013; 381:40–46.
Nohara A, Otsubo Y, Yanagi K, et al. Safety and efficacy of lomitapide in japanese patients with homozygous familial hypercholesterolemia (HoFH): results from the AEGR-733–301 long-term extension study. J Atheroscler Thromb 2019; 26:368–377.
Bergmark BA, Marston NA, Bramson CR, et al. Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation 2022; 145:1377–1386.